Lipidomic Analysis of α-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment

Mol Cell. 2019 Mar 7;73(5):1001-1014.e8. doi: 10.1016/j.molcel.2018.11.028. Epub 2018 Dec 4.

Abstract

In Parkinson's disease (PD), α-synuclein (αS) pathologically impacts the brain, a highly lipid-rich organ. We investigated how alterations in αS or lipid/fatty acid homeostasis affect each other. Lipidomic profiling of human αS-expressing yeast revealed increases in oleic acid (OA, 18:1), diglycerides, and triglycerides. These findings were recapitulated in rodent and human neuronal models of αS dyshomeostasis (overexpression; patient-derived triplication or E46K mutation; E46K mice). Preventing lipid droplet formation or augmenting OA increased αS yeast toxicity; suppressing the OA-generating enzyme stearoyl-CoA-desaturase (SCD) was protective. Genetic or pharmacological SCD inhibition ameliorated toxicity in αS-overexpressing rat neurons. In a C. elegans model, SCD knockout prevented αS-induced dopaminergic degeneration. Conversely, we observed detrimental effects of OA on αS homeostasis: in human neural cells, excess OA caused αS inclusion formation, which was reversed by SCD inhibition. Thus, monounsaturated fatty acid metabolism is pivotal for αS-induced neurotoxicity, and inhibiting SCD represents a novel PD therapeutic approach.

Keywords: Parkinson’s disease; alpha-synuclein; diglyceride; inclusions; lipid droplets; oleic acid; stearoyl-CoA-desaturase; synucleinopathy; tetramer; triglyceride; unsaturated fatty acid.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiparkinson Agents / pharmacology*
  • Caenorhabditis elegans / drug effects
  • Caenorhabditis elegans / enzymology
  • Caenorhabditis elegans / genetics
  • Cell Line
  • Cerebral Cortex / drug effects
  • Cerebral Cortex / enzymology
  • Cerebral Cortex / pathology
  • Diglycerides / metabolism
  • Disease Models, Animal
  • Dopaminergic Neurons / drug effects
  • Dopaminergic Neurons / enzymology
  • Dopaminergic Neurons / pathology
  • Drug Discovery / methods*
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • Induced Pluripotent Stem Cells / drug effects
  • Induced Pluripotent Stem Cells / enzymology
  • Induced Pluripotent Stem Cells / pathology
  • Lipid Droplets / drug effects
  • Lipid Droplets / enzymology
  • Lipid Metabolism / drug effects*
  • Metabolomics / methods*
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Molecular Targeted Therapy
  • Nerve Degeneration
  • Neural Stem Cells / drug effects
  • Neural Stem Cells / enzymology
  • Neural Stem Cells / pathology
  • Neurons / drug effects*
  • Neurons / enzymology
  • Neurons / pathology
  • Oleic Acid / metabolism
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / enzymology
  • Parkinson Disease / genetics
  • Parkinson Disease / pathology
  • Rats, Sprague-Dawley
  • Saccharomyces cerevisiae / drug effects
  • Saccharomyces cerevisiae / enzymology
  • Saccharomyces cerevisiae / genetics
  • Stearoyl-CoA Desaturase / antagonists & inhibitors*
  • Stearoyl-CoA Desaturase / metabolism
  • Triglycerides / metabolism
  • alpha-Synuclein / genetics
  • alpha-Synuclein / toxicity*

Substances

  • Antiparkinson Agents
  • Diglycerides
  • Enzyme Inhibitors
  • Triglycerides
  • alpha-Synuclein
  • Oleic Acid
  • Stearoyl-CoA Desaturase